[headline announcement Nuggets]

Dongyue Group (00189): Dongyue Fluorosilicon Technology and Dongyue hydrogen Energy enter into "Framework Agreement on Raw material supply, Product sales and other transactions"

Dongyue Group announced that Dongyue Fluorosilicon Technology, a direct wholly-owned subsidiary of the company, entered into an agreement with Dongyue hydrogen Energy on August 2, 2022. Dongyue Fluorosilicon Technology and its subsidiaries (1) supply Dongyue raw materials and supporting services to Dongyue hydrogen Energy for its production and operation, and (2) purchase hydrogen energy raw materials and products and supporting services from Dongyue hydrogen Energy for the production and operation of the Group. The agreement is valid until December 31, 2022.

Among them, the total amount paid by Dongyue hydrogen to Dongyue fluorosilicon technology does not exceed about 93.189 million yuan, while the total amount paid by Dongyue fluorosilicon technology and its subsidiaries does not exceed about 39.304 million yuan.

Comments:Dongyue shares are the leader of fluorinated polymer materials, with large scale advantages and rich categories. The company has the advantage of fluorine chemical industry chain integration, R142b, R22 and other upstream raw materials are completely self-sufficient, with the gradual expansion of new production capacity.

The industrial boom has improved across the board since 2021, and the prices of PTFE, FKM, FEP and other major products have all increased compared with the same period last year; PVDF has nearly doubled due to the demand for downstream new energy and lithium power, and the company's production capacity and technology reserves are sufficient, so it can flexibly adjust the production line according to market conditions.

The company's Dongyue hydrogen Energy Company mainly deals in hydrogen fuel cell proton exchange membranes and upstream raw materials, with a capacity reserve of 500000 square meters, which is the only enterprise in China that can achieve large-scale supply, and is expected to achieve sales of 30, 000 to 40, 000 square meters this year. In the long run, the hydrogen fuel cell has broad prospects in the future, and the company has an obvious competitive advantage by seizing the high-quality track ahead of time.

On March 23, 2022, the National Development and Reform Commission issued the medium-and long-term Plan for the Development of hydrogen Energy Industry (2021-2035). Beijing, Shanghai, Guangzhou, Zhengzhou (Henan) and Zhangjiakou (Hebei) are selected in the first batch of demonstration urban agglomeration, and the second batch of demonstration urban agglomeration such as Sichuan-Chongqing region and Hubei Province is expected to start.

[key announcement Nuggets]

Mega Ophthalmology-B (06622): patients were enrolled in the Phase III clinical trial of NVK002 in the treatment of myopia

Zhaoke Ophthalmology announced that the two-year Phase III clinical trial of NVK002, one of the company's core products ("China CHAMP") and the simultaneous one-year Phase III bridging clinical trial ("Mini CHAMP") were completed on July 21, 2022 and July 28, 2022, respectively.

Comments:Zhaoke Ophthalmology Co., Ltd. is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of ophthalmic therapy to meet the huge medical needs in China. Through independent research and development or licensed introduction, a comprehensive ophthalmic drug pipeline containing 25 drug candidates has been established, covering most major ophthalmic indications affecting the anterior and posterior segments.

The R & D expenditure increased from 80 million to 220 million yuan in 2021, mainly for cyclosporine A (CsA) gel III clinical trials, R & D team expansion and employee equity incentives; the adjusted net loss increased from 95.69 million to 230 million. The core cash expenditure is about 360 million, which is generally controllable.

The commercialization of the company in 2022 is about to take an important step. Specifically, Bemesu timolol, which is expected to treat glaucoma, is expected to be listed this year and become the company's first commercial product (potential domestic first imitation, submitted to ANDA in October 2020). In addition, in March 2022, the company signed strategic cooperation agreements with three pharmaceutical commercial logistics companies, Sinopharm Group Distribution Center Co., Ltd., Shanghai Pharmaceutical Holdings Co., Ltd. And China Resources Pharmaceutical Business Group Co., Ltd., focusing on distribution.

NVK002 in this clinical trial is an experimental new type of topical eye solution to control the deepening of myopia in children and adolescents. The Chinese CHAMP trial, led by Wang Ningli of Beijing Tongren Hospital, involved 19 centers and enrolled 777 patients within 4 months. The mini-CHAMP trial, led by qu Xiaomei of Otorhinolaryngology Hospital affiliated to Fudan University and Professor Yang Xiao of Sun Yat-sen Ophthalmology Center of Sun Yat-sen University, involved 18 centers.

Great Wall Motor (02333): buy back 108 million H shares, with a cumulative cost of about HK $1.594 billion

Great Wall Motor announced that as of July 31, 2022, the company had accumulated about 108 million H shares in the company, accounting for 1.18% of the company's total issued share capital and 3.57% of the total issued H shares as at July 31, 2022. The price range is HK $12.42 to HK $16.98 per share, and the total funds used is about HK $1.594 billion.

Comments:Great Wall Motor Co., Ltd. is the largest SUV manufacturer in China, with two brands of Harvard and Great Wall, four vehicle production bases and independent supporting capabilities of core components such as engines and transmissions.

In the first half of the year, the proportion of models based on lemon platform (including lemon hybrid DHT), tank platform and coffee intelligence increased to 69% from 57% in 2021, intelligent vehicles increased to 85% from 74% in 2021, and vehicles worth more than 200000 yuan increased to 14% from 10% in 2021. Product structure continues to be optimized, superimposed Harvard, tanks and other brand models benefit from the purchase tax halving policy, providing support for the company to improve profitability.

The company changed the underlying structure, the enterprise orientation changed from "automobile manufacturing enterprise" to "user service operation enterprise", and the business model changed to "product + software + service", which laid the foundation for it to effectively tap the market demand. In the critical period of the reform of electric intelligence in the automotive industry, the company is a traditional independent car company with early transformation. The long-term accumulation of core technology and the product strategy of each brand focusing on subdivision are important driving forces for the company's continuous transformation of electric intelligence.

Prior to the performance forecast, the company expected to achieve a net profit of 53-5.9 billion yuan in the first half of 2022, an increase of 50.2%-67.2% over the same period last year, and a non-return net profit of 18-2.3 billion yuan.

[list of important announcements for Hong Kong stocks]